Previous 10 | Next 10 |
InvestorPlace - Stock Market News, Stock Advice & Trading Tips AbCellera Biologics ( ABCL ): Impressive sales growth is very promising for this firm and its antibody discovery platform. SIGA Technologies ( SIGA ): Improved profitability and a remarkable ROE make it very ...
NEW YORK, April 08, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today announced that management will present at the 21 st A...
Ovid Therapeutics press release (NASDAQ:OVID): Q4 GAAP EPS of -$0.38 misses by $0.22. Cash and cash equivalents as of December 31, 2021 was $187.8M. For further details see: Ovid Therapeutics GAAP EPS of -$0.38 misses by $0.22
Ovid executing on its strategy to build a leading epilepsy pipeline OV329 expected to enter the clinic in 2022 Organization reshaped to reduce personnel by 20% and increase operational efficiency Targeted business development continues to support the pipeline ...
NEW YORK, March 04, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people affected by epilepsies and rare neurological disorders, today announced that management will participate virtu...
– Ovid to License Gaboxadol to Healx – – Healx to Explore Gaboxadol in Combination Therapies for Fragile X, Other Indications – NEW YORK, N.Y. and CAMBRIDGE, United Kingdom, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics (NASDAQ:OVID) (...
Exclusive license from AstraZeneca adds a unique candidate and a broad library of compounds to Ovid’s franchise of potential first-in-class anti-epileptic therapies Collaboration with Dr. Stephen Moss, founder of Tufts Laboratory for Basic and Translational Neuroscience Res...
Ovid Therapeutics (NASDAQ:OVID): Q3 GAAP EPS of -$0.17 beats by $0.03. Company ended the third quarter of 2021 with cash and cash equivalents of $201.8 million. Press Release For further details see: Ovid Therapeutics EPS beats by $0.03
Ovid is implementing its business development program which intends to secure a series of opportunities that complement and enhance its pipeline of precision and small-molecule CNS medicines A development program for soticlestat, which Ovid licensed to Takeda, has begun enrolling ...
NEW YORK, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that it has appointed Kevin Fitzgerald, Ph.D., to its Boa...
News, Short Squeeze, Breakout and More Instantly...
Ovid Therapeutics Inc. Company Name:
OVID Stock Symbol:
NASDAQ Market:
Ovid Therapeutics Inc. Website:
Neurologists/epileptologists Dr. Imad Najm of the Cleveland Clinic Neurological Institute and the Cleveland Clinic Epilepsy Center, and Dr. Raman Sankar, the Emeritus Chief of Pediatric Neurology at UCLA Health, appointed to Ovid’s Scientific Advisory Board (SAB) Neuroscientists Dr. Ja...
Sustained exposure to OV329 in preclinical models reduced GABA-aminotransferase (GABA-AT) activity, increased steady state GABA levels in the brain, and induced phasic and tonic inhibition OV329 demonstrated anti-convulsant effects in mice, reducing the severity of status epilepticus and pr...
The Phase 1 study for OV888/GV101 capsule met its objective, demonstrating a favorable safety and tolerability profile with no serious adverse events Secondary endpoint results indicate that the target pharmacokinetic profile was achieved at the targeted clinical dose, supporting once daily d...